CL2024000208A1 - Gedatolisib y sus combinaciones para usarse en el tratamiento de cáncer - Google Patents

Gedatolisib y sus combinaciones para usarse en el tratamiento de cáncer

Info

Publication number
CL2024000208A1
CL2024000208A1 CL2024000208A CL2024000208A CL2024000208A1 CL 2024000208 A1 CL2024000208 A1 CL 2024000208A1 CL 2024000208 A CL2024000208 A CL 2024000208A CL 2024000208 A CL2024000208 A CL 2024000208A CL 2024000208 A1 CL2024000208 A1 CL 2024000208A1
Authority
CL
Chile
Prior art keywords
gedatolisib
week
administration
cancer
period
Prior art date
Application number
CL2024000208A
Other languages
English (en)
Spanish (es)
Inventor
Francis Sullivan Brian
Gavin Laing Lance
Original Assignee
Celcuity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celcuity Inc filed Critical Celcuity Inc
Publication of CL2024000208A1 publication Critical patent/CL2024000208A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024000208A 2021-07-26 2024-01-24 Gedatolisib y sus combinaciones para usarse en el tratamiento de cáncer CL2024000208A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163225707P 2021-07-26 2021-07-26
US202163285327P 2021-12-02 2021-12-02

Publications (1)

Publication Number Publication Date
CL2024000208A1 true CL2024000208A1 (es) 2024-07-19

Family

ID=82932627

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024000208A CL2024000208A1 (es) 2021-07-26 2024-01-24 Gedatolisib y sus combinaciones para usarse en el tratamiento de cáncer

Country Status (11)

Country Link
US (3) US12350276B2 (cg-RX-API-DMAC7.html)
EP (1) EP4376848A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024529430A (cg-RX-API-DMAC7.html)
KR (1) KR20240040768A (cg-RX-API-DMAC7.html)
AU (2) AU2022320615B2 (cg-RX-API-DMAC7.html)
CA (1) CA3227191A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000208A1 (cg-RX-API-DMAC7.html)
IL (1) IL310243A (cg-RX-API-DMAC7.html)
MX (1) MX2024001266A (cg-RX-API-DMAC7.html)
TW (1) TW202320795A (cg-RX-API-DMAC7.html)
WO (1) WO2023009438A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025049962A1 (en) * 2023-08-31 2025-03-06 Aadi Bioscience, Inc. Combination cancer treatments with a composition comprising an mtor pathway inhibitor
US20260053814A1 (en) * 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
JP5190271B2 (ja) 2005-01-14 2013-04-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としての5員の環付加複素環式ピリミジン
US10022381B2 (en) 2008-05-23 2018-07-17 Pfizer Inc. Triazine compounds as PI3 kinase and mTOR inhibitors
MY155653A (en) 2008-05-23 2015-11-13 Wyeth Llc Triazine compounds as p13 kinase and mtor inhibitors
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
KR102186969B1 (ko) 2010-10-25 2020-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
EP3216792B1 (en) 2012-03-29 2020-05-27 G1 Therapeutics, Inc. Lactam kinase inhibitors
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
EP3116547B1 (en) 2014-03-14 2019-06-05 Pfizer Inc Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
HUE055928T2 (hu) 2014-12-17 2022-01-28 Pfizer PI3K/MTOR-inhibitorok készítményei intravénás adagolásra
LT3672571T (lt) 2017-08-25 2021-12-10 Pfizer Inc. Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą
US12109308B2 (en) 2018-06-07 2024-10-08 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yljcarbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
EP3863618A1 (en) * 2018-10-08 2021-08-18 F. Hoffmann-La Roche AG Methods of treating cancer with pi3k alpha inhibitors and metformin

Also Published As

Publication number Publication date
AU2022320615B2 (en) 2025-08-21
US20260174772A1 (en) 2026-06-25
KR20240040768A (ko) 2024-03-28
EP4376848A1 (en) 2024-06-05
AU2022320615A1 (en) 2024-03-14
JP2024529430A (ja) 2024-08-06
TW202320795A (zh) 2023-06-01
IL310243A (en) 2024-03-01
US20230022525A1 (en) 2023-01-26
CA3227191A1 (en) 2023-02-02
WO2023009438A1 (en) 2023-02-02
US20250345342A1 (en) 2025-11-13
US12350276B2 (en) 2025-07-08
MX2024001266A (es) 2024-04-16
AU2025223785A1 (en) 2025-09-18

Similar Documents

Publication Publication Date Title
CO6361942A2 (es) Terapia de combinacion con epoxicetonas peptidicas
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
AR103118A1 (es) Tratamientos médicos basados en anamorelina
AR120399A1 (es) Un método de tratamiento de un cáncer positivo para dll3
CO2021004681A2 (es) Uso de reboxetina para el tratamiento de narcolepsia
CO6220969A2 (es) Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo
CO6592015A2 (es) Métodos y composiciones para reducir o prevenir la cladificación vascular durante el tratamiento de diálisis peritoneal
MX2019004402A (es) Metodos para el tratamiento de las condiciones relacionadas con la inflamacion utilizando moduladores antiinflamatorios y metabolicos pluripotentes.
CO2022017877A2 (es) Terapia de combinación para amiloidosis de la ttr
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
CO2022008001A2 (es) Métodos para el tratamiento de trastornos depresivos
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
MX2022001450A (es) Metodo de tratamiento del cancer.
MX2024001266A (es) 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-d imorfolin-4-il-1,3,5-triazin-2-il)fenil]urea (gedatolisib) y sus combinaciones para usarse en el tratamiento de cancer.
CL2022001477A1 (es) Uso de un abridor de canal de potasio kv7 para tratar el dolor
MX2025006279A (es) Tratamientos contra el cancer mediante un inhibidor de prmt5 y un inhibidor de mat2a
MX2024011932A (es) Combinaciones farmaceuticas y metodos de uso del compuesto de amino-pirrolopirimidinona
AR126566A1 (es) Métodos para el tratamiento contra el cáncer con 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]urea
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor
PE20242177A1 (es) Tratamiento del glioma de bajo grado con mirdametinib
MX2023013514A (es) Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
UY39593A (es) Tratamiento para tumores sólidos malignos
MX2022001227A (es) Metodos de tratamiento del cancer multifocal.